MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• MET-targeted therapies historically focused on MET expression, yielding limited success.
• Genomic alterations, including MET amplification, mutations (e.g., exon 14 skipping), and fusions, are now recognized as oncogenic drivers.
• MET expression alone is an insufficient predictor of response to MET-targeted therapy.

Purpose of the Study:

• To evaluate the utility of diagnostic techniques for identifying MET alterations.
• To review the roles of different classes of MET-targeted therapies in cancers with MET amplification, mutation, and fusion.
• To assess the therapeutic implications of various MET alterations.

Main Methods:

• Literature review and synthesis of data on diagnostic methods (FISH, NGS).
• Analysis of clinical trial data for MET-targeted agents.
• Evaluation of therapeutic efficacy across different MET alteration categories.

Main Results:

• High-level MET amplification and specific mutations/fusions are key oncogenic drivers.
• The efficacy of MET tyrosine kinase inhibitors varies based on the specific MET alteration.
• Agents targeting MET exon 14 skipping alterations show early promise; MET fusions require further investigation.
• Increasing MET amplification levels correlate with increased likelihood of benefit, but optimal diagnostic cut-offs are debated.

Conclusions:

• Sensitive diagnostic methods are crucial for identifying actionable MET alterations.
• Tailoring MET-targeted therapies to specific genomic alterations is essential for maximizing patient benefit.
• Further research is needed to fully elucidate the therapeutic potential of targeting MET fusions and to establish standardized diagnostic criteria.